NSCLC Adenocarcinoma
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (NCT03252938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-08-15 |
| Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (NCT02121899) | Myriad Genetic Laboratories, Inc. | 2015-04-01 |
Track NSCLC Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.